GNH USA

Europe — EMA

Icatibant Stada

GNH USA supplies Icatibant Stada (Icatibant), a bradykinin B2 receptor antagonist for hereditary angioedema attacks. Request a quote for global supply.

Icatibant

Request sourcing

1
Pack/s

What is Icatibant?

Icatibant, the active ingredient in Icatibant Stada, is a bradykinin B2 receptor antagonist presented as a subcutaneous formulation for subcutaneous use. It blocks the bradykinin B2 receptor, reducing vasodilation and vascular permeability, and is indicated for the treatment of acute hereditary angioedema attacks in adults.

GNH USA supplies Icatibant Stada as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide under strict quality standards and reliable cold‑chain logistics where required and ensuring timely delivery.

What is Icatibant used for?

Icatibant is used to treat hereditary angioedema by targeting the bradykinin pathway. - Hereditary angioedema type I: reduces swelling during acute attacks. - Hereditary angioedema type II: reduces swelling during acute attacks. - Hereditary angioedema with normal C1 inhibitor: reduces swelling during acute attacks. - Hereditary angioedema attacks in patients previously treated with C1‑inhibitor: offers an alternative mechanism of action.

What are the side effects of Icatibant?

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain - Redness at injection site - Nausea - Headache

Serious or Rare Side Effects: - Anaphylaxis - Severe angioedema - Hypotension

What precautions apply to Icatibant?

When using icatibant, certain precautions should be observed to ensure patient safety. - Pregnancy: consult healthcare provider; safety not established. - Breastfeeding: caution; unknown excretion in milk. - Renal impairment: use with caution; limited data. - Concomitant ACE inhibitors: monitor for increased angioedema risk. - Known hypersensitivity: contraindicated in patients allergic to icatibant or excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Icatibant interact with?

Icatibant can interact with other medicines; awareness of major and moderate interactions helps manage risk.

Major Interactions (Avoid): - ACE inhibitors: may increase risk of angioedema. - Angiotensin receptor blockers: may potentiate bradykinin‑mediated effects. - Concomitant bradykinin B2 receptor antagonists: additive pharmacologic effect.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask early signs of hypotension. - NSAIDs: can exacerbate angioedema in susceptible individuals. - C1‑inhibitor concentrate: no direct interaction but monitor clinical response.

Frequently asked questions

What is Icatibant Stada used for?+
Icatibant Stada is a prescription‑only medication indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult patients. By rapidly blocking the bradykinin B2 receptor, it helps to reduce swelling of the skin, gastrointestinal tract, and airway that occur during HAE episodes.
How does icatibant work?+
Icatibant works as a competitive antagonist at the bradykinin B2 receptor, a G‑protein‑coupled receptor that mediates vasodilation and increased vascular permeability. When icatibant binds to this receptor, it prevents endogenous bradykinin from activating the signaling cascade, thereby limiting the fluid leakage and swelling that characterize hereditary angioedema attacks.
What is the usual dose of icatibant?+
The dosage of icatibant is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Typically, a single subcutaneous injection is administered at the onset of an HAE attack, and additional doses may be given if symptoms persist, following the prescriber’s specific instructions. No standardized dosing regimen is provided here.
Is icatibant safe during pregnancy or breastfeeding?+
Safety data for icatibant in pregnancy and lactation are limited. The product label advises that it should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should consult their healthcare provider because it is unknown whether icatibant is excreted in breast milk.
How do I order Icatibant Stada from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity of Icatibant Stada. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and the necessary import documentation.
How does icatibant compare with other hereditary angioedema treatments?+
Icatibant is a bradykinin B2 receptor antagonist, whereas other approved therapies include C1‑inhibitor concentrates (plasma‑derived or recombinant) and kallikrein inhibitors. Icatibant provides a rapid, subcutaneous option that directly blocks bradykinin, while C1‑inhibitor products replace deficient protein and kallikrein inhibitors target upstream activation. Choice of therapy depends on patient preference, attack severity, and physician assessment.
What are the storage and handling requirements for icatibant?+
Icatibant should be stored in a refrigerator at 2‑8 °C (36‑46 °F). The product must be kept in its original packaging, protected from light, and must not be frozen or shaken. If a temporary temperature excursion occurs, the vial should be inspected for any changes before use, and any compromised product must be discarded.
How is icatibant administered?+
Icatibant is administered by subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection is performed by a trained healthcare professional or, after appropriate instruction, by the patient or caregiver. The recommended injection site should be rotated for subsequent doses, and the needle should be disposed of in a sharps container following local regulations.
What are the most serious risks to watch for with icatibant?+
The most serious adverse reactions associated with icatibant include anaphylaxis, severe angioedema, and sudden hypotension, which can be life‑threatening if not treated promptly. Patients should be monitored after the first injection for signs of allergic reaction, and any sudden swelling, difficulty breathing, or drop in blood pressure should trigger immediate medical attention.
Who should not use icatibant?+
Icatibant is contraindicated in individuals with a known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients with severe renal impairment, pregnant or nursing women, and those taking ACE inhibitors or other drugs that increase bradykinin levels, as the risk of angioedema may be heightened. Clinical judgment determines suitability.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Icatibant
Route
Subcutaneous Use
Manufacturer
Stadapharm Gmbh
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU